Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform.

As a practicing interventional cardiologist, West remembers an earlier time in which the stents were barely deliverable. Each available platform had marked differences and each had its benefits and drawbacks.
“It’s fair to say that, if you look at the world of drug-eluting stents, they’ve evolved enormously,” West told Drug Delivery Business News. “They’ve just changed hugely.”
Get the full story at our sister site, Drug Delivery Business News.